Agree with most of these. Putting aside medical devices and just looking at 'true bios', i.e. drug development, the FA and myriad of product development complexities is too complicated for anyone who doesn't have a deep knowledge of the field, so your average punter is completely in the dark. It follows then that you should let someone else do the work for you. Early stage bios which don't have sophisticated investor backing by a reputable life science VC/investor should be avoided in my view. Many make the mistake of classing a 'deal' with big pharma as an evaluation of your drug candidate, which isn't that hard to get. If someone who understands the science and the field isn't willing to put big $ on the table then why should you? Good examples of these are OPT and VLA.
